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Abstract
Introduction: Involvement of major vascular structures has been considered a limiting factor for
resecting advanced tumors. The objective of this study was to evaluate the outcome after con-
comitant retroperitoneal tumor and vascular resection with prosthetic replacement of the aorta/
vena cava.
Methods: The authors reviewed a 5-year series of eight patients with a median age of 50 years
(range 11–68 years) who had undergone resection of a retroperitoneal tumor and concomitant
resection and replacement of the abdominal aorta, inferior vena cava, or both. The histologic
diagnoses were sarcoma (five patients), teratoma (one), transitional cell carcinoma (one), and
ganglioneuroma (one). The main outcome measures were early (< 30 days) and late (‡ 30 days)
surgical morbidity and mortality. Secondary endpoints were vascular graft patency and tumor-free
survival. Two patients underwent combined graft replacement of the aorta and vena cava. Single
aortic and vena cava graft replacement were each done in three patients.
Results: Two patients showed early surgical morbidity necessitating reoperation for a thrombotic
graft occlusion. No patient died during the early course of the follow-up. During a median follow-up
of 14 months (range 1–56 months), two patients had late surgical morbidity. The median tumor-
free survival for patients with malignancy was 14 months (range 1–54 months). One patient
developed locoregional tumor recurrence, and two developed distant metastases. The median
survival for patients with malignancy was 14 months (range 1–60 months).
Conclusions: An aggressive surgical approach for otherwise unresectable retroperitoneal tumors
with vascular resection and prosthetic vascular replacement is justified in selected cases and has
acceptable morbidity and mortality.
Owing to the absence of early symptoms, retroperi-toneal tumors are often not diagnosed until the
disease is at an advanced stage with a large tumor and
involvement of surrounding structures. The involvement
of major vascular structures has traditionally been con-
sidered a limiting factor or even a relative contraindication
to resection of advanced tumors because of the poor
long-term prognosis and high surgical risk. Nevertheless,
during recent decades several studies have shown
promising results after concomitant tumor and vascular
resection at various localizations.1–7 The aorta and the
vena cava have rarely been replaced in patients with
malignancy because of the magnitude and high risk of the
operation.1 The operative treatment of tumors involving
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the aorta or vena cava (or both) has been improved by
the introduction of polytetrafluoroethylene (PTFE) grafts
for vascular reconstruction.8 Even so, the surgery needed
to achieve complete tumor resection is challenging.
Determining the utility of retroperitoneal tumor resec-
tion including resection and prosthetic replacement of the
aorta/vena cava is difficult because few studies have
dealt with the vascular complications associated with
major arterial or venous procedures and simultaneous
tumor resection.1,2,9,10
The aim of this study was to determine whether this
extended surgical procedure is justified. We reviewed the
outcomes of patients who underwent concomitant retro-
peritoneal tumor resection and vascular resection com-
bined with prosthetic replacement of the abdominal aorta
or inferior vena cava (or both).
MATERIALS AND METHODS
We reviewed the records of eight patients (four women)
with a median age of 50 years (range 11–68 years)
treated from September 1999 to September 2004 by an
oncologic procedure for vascular involvement of a retro-
peritoneal neoplasm requiring concomitant resection of
the infrarenal aorta or inferior vena cava (or both) with a
vascular replacement prosthesis (Fig. 1). Exclusion cri-
teria were vascular resection without prosthetic recon-
struction, reconstruction of the superior vena cava and
thoracic aorta, and renal cell carcinoma requiring only
removal of a tumor thrombus in the vena cava.
Long-term follow-up was obtained in seven of eight
patients. One patient (Table 1) was lost to follow-up
1 month after the operation. The main outcome measures
were early (< 30 days) and late (‡ 30 days) surgical
morbidity and mortality. Secondary endpoints were vas-
cular graft patency and tumor-free survival. Perioperative
and postoperative morbidity/mortality, surgical procedure,
and histopathologic diagnosis of the tumor were identified
by a review of medical records and pathology reports.
The patency of the vascular replacement was evaluated
by a review of follow-up flow duplex imaging, computed
tomographic (CT) scans, or clinical examination. Survival
and tumor recurrence were determined by a review of
medical reports.
Single aortic or vena cava graft replacement was each
done in three patients (Table 1). Two patients underwent
combined graft replacement of the aorta and vena cava
(Fig. 2). For vascular prosthetic replacement a PTFE graft
was used in all patients. Aortic prosthetic replacement
(diameters 8–16 mm) included only the infrarenal aorta.
Vena cava prosthetic replacement (diameters 16–20 mm)
was performed below the renal veins in all but two patients.
One patient underwent reimplantation of the left renal vein.
Vascular resection and replacement were done without
extracorporeal circulation in all patients. Intraoperative
heparin sodium was routinely administered before vas-
cular clamping. Postoperatively, partial thromboplastin
time-controlled heparin sodium was administered to five
patients and low-molecular-weight heparin to three pa-
tients for 5 days. Subsequently, Coumarin anticoagulant
was given to four patients and chronic antiplatelet therapy
to the other four. The vascular replacement procedures
were performed electively in conjunction with tumor
resection in six of eight patients. Vascular replacement
was required as an emergency procedure in two patients
because of a vascular injury that occurred during resec-
tive oncologic surgery.
The tumor was malignant in seven of the eight patients.
The pathologic diagnosis was sarcoma in five patients,
teratoma in one, transitional cell carcinoma in one, and
benign ganglioneuroma in one (Table 1). In seven of the
eight patients, histopathologic examination revealed di-
rect vascular infiltration by the tumor (Fig. 3). Negative
margin resection (R0) was achieved in four patients and
positive microscopic/negative gross margin resection
(R1) in three. Only one of the patients (patient 6) showed
a positive microscopic margin (R1) in the resected vas-
cular structure; in two other patients microscopic tumor
Figure 1. Intraoperative view of the liposarcoma with infiltration
of aorta and vena cava. CIA: common iliac arteries; CIV:
common iliac veins; A: aorta.
Fueglistaler et al.: Vascular Resection and Retroperitoneal Tumors 1345
involvement was found in the surrounding soft tissue.
Macroscopic tumor residuum (R2) was left in the patient
with a benign tumor (Table 1).
Five patients were operated on for primary lesions and
two patients for locoregional recurrence (patients 1 and
8). Retroperitoneal metastasis was the reason for the
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Figure 2. Combined replacement of aorta and vena cava after
concomitant retroperitoneal tumor and vascular resection.
A: aortic bifurcation prosthesis 16/8 mm); VC: vena cava
bifurcation prosthesis (20/10 mm).
Figure 3. Microscopic view of vascular tumor infiltration. Arrow
indicates vascular wall infiltration of the vena cava by the
liposarcoma.
operation in one patient (patient 2). One patient (patient
3) was operated on 2 months after prosthetic replace-
ment of an aortic aneurysm because the histopathologic
examination revealed an intimal sarcoma of the aorta.
Resection of contiguous organs was performed in five
patients (Table 1).
The preoperative clinical performance status was de-
fined according to the American Society of Anesthesiol-
ogists (ASA) classification: Three patients were classified
as ASA 2 and five as ASA 3. The mean operating time
was 340 minutes. Seven patients required blood trans-
fusion perioperatively (median requirement 4 units; range
0–15 units). Preoperatively, two patients underwent
combined chemotherapy/radiotherapy, and one had
chemotherapy only (Table 1). Postoperatively, chemo-
therapy was administered to three patients and radio-
therapy to one. Preoperative diagnostic evaluation
included chest radiography, CT scan of the abdomen, or
magnetic resonance imaging (or a combination of these
tests) in all patients and CT- or ultrasound-guided biopsy
in five patients (Fig. 4). Perioperatively, all patients were
given antibiotic prophylaxis with a second-generation
cephalosporin for 24 hours.
RESULTS
Two of eight patients showed early surgical morbidity
after being reoperated for a thrombotic graft occlusion.
The patient (patient 7) operated on for vena cava
replacement and reimplantation of the left renal vein had
to be reoperated 24 hours later for a graft thrombectomy
and prosthetic reconstruction of the left renal vein. This
patient also developed esophagitis and kidney failure
requiring hemodialysis. Another patient (patient 2) was
reoperated for a graft bifurcation thrombectomy 6 hours
after aortic replacement. The latter patient had a pulmo-
nary infection and Clostridium difficile colitis. Two patients
(patients 5 and 8) developed urinary infections, causing
pyelonephritis in one patient (patient 5). None of the pa-
tients died as a result of the surgical procedure.
During a median follow-up of 14 months (range 1–56
months; mean 18 months), two of seven patients had late
surgical morbidity. One patient (patient 5) was reoperated
4 months after replacement of the vena cava and
resection of the right tumor-involved ureter; nephrectomy
was done for ureteral leakage that caused a urinoma.
One patient (patient 7) underwent CT-guided drainage
of a retroperitoneal hematoma 1 month postoperatively.
This patient also had a thrombotic occlusion of the left
renal vein graft 2 months after prosthetic replacement of
the vena cava and left renal vein. Because kidney func-
tion was normal, reoperation was not indicated. There
were no reported graft infections.
The median tumor-free survival for patients with
malignancy was 14 months (range 1–54 months). One
patient developed locoregional tumor recurrence (patient
4) and died of it 11 months after operation. Two patients
developed distant metastases (patients 1 and 6). One of
these patients (patient 6) had an abdominal wall (inci-
sional) metastasis necessitating abdominal wall resection
after 22 months. The other patient (patient 1) developed
several metastases in the lung. The median survival for
patients with malignancy was 14 months (range 1–60
months).
Graft patency failure occurred in two patients (patients
2 and 7) who were reoperated during the early follow-up.
Patient 7 also developed a thrombotic occlusion of the left
renal vein graft 2 months postoperatively, as described
above.
DISCUSSION
Patients who undergo concomitant resection of a retro-
peritoneal tumor and major vascular structures usually
exhibit considerable perioperative morbidity because of
the extent of the surgical procedure. In addition, these
patients may be in poor general condition as a result of
advanced disease and sometimes preoperative chemo-
therapy. In this study only two patients showed vascular
Figure 4. Axial magnetic resonance image demonstrates vas-
cular infiltration by the retroperitoneal liposarcoma. A: aorta; VC:
vena cava.
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problems that required reoperation, and no sequelae re-
sulted. Nonvascular complications during the early course
of follow-up were minor. No perioperative deaths occurred,
underlining the feasibility of this technically demanding
surgical procedure in carefully selected patients.1,10–13 In
contrast, one study showed an early morbidity incidence of
44% after vena cava replacement, including major com-
plications such as intraoperative coagulopathy with graft
occlusion and graft infection leading to death.1 In another
series similar to the present one but using different vascular
procedures, the early morbidity was 19% in patients with
aortic and vena cava replacement.10
During the median follow-up of 14 months, both median
tumor-free survival and median survival for the seven
patients with malignancies were 14 months; only one
patient died after 11 months. The small number of pa-
tients, the different types of tumor, and the rather short
follow-up period precluded definitive conclusions about
the impact of these operations on survival. Moreover, the
present study was primarily concerned with the rationale
for, and the feasibility of, a combined major surgical ap-
proach as part of extended therapeutic management.
Vascular intervention may be necessary to cure or
palliate symptoms by concomitant resection and
replacement of major vessels infiltrated by a tumor.
Alternatively, a rescue procedure may be necessary be-
cause of an intraoperative vascular injury, as was the
case in two of our patients. Precise preoperative planning
of the surgical approach is important for complete tumor
resection combined with low perioperative morbidity. In
the case of sarcomas (the main tumor type in this study),
complete tumor resection is the main predictor of a low
rate of tumor recurrence and increased survival.11,14–16 In
a series of 500 patients with retroperitoneal sarcoma, the
survival rate was significantly reduced in patients whose
resection was incomplete,17 but other series have found
no long-term survivors even after complete resection of
retroperitoneal sarcoma with major vascular resection.9,18
For retroperitoneal sarcoma, complete tumor resection
is reported in 59% to 90% of patients, with a higher rate
for primary tumors compared with recurrent tu-
mors.11,15,17,19,20 In the present series, complete resec-
tion (R0) was achieved in three of the five patients with
sarcoma, one of whom was operated on for a recurrent
tumor.
Three of seven patients with malignancy developed
recurrence, giving a median tumor-free survival of 14
months, which is consistent with earlier findings of tumor
recurrence in more than 50% of patients after prosthetic
replacement of the vena cava for malignancy during a
median follow-up of 16 months.21
A contiguous organ was resected in more than half of
our patients, consistent with other series of retroperito-
neal sarcoma, who have reported additional organ
resection in 44% to 93%.15–17,21,22 For retroperitoneal
tumors, multivisceral resection is done not only to achieve
negative surgical margins but also to facilitate the surgical
procedure technically.21 One study found histopathologic
confirmation of tumor involvement in only 4% of resected
organs.16
Nearly all of our patients received multimodal treat-
ment, depending on tumor biology and tumor involvement
of surgical margins (Table 1). Although some studies
have shown reduced disease recurrence or even im-
proved patient survival after radiotherapy,11,14,15,17 mul-
timodal treatment for the management of retroperitoneal
sarcoma remains controversial. This is because the
radiation dose is limited by the tolerance of the sur-
rounding structures, the volume of the retroperitoneum to
be irradiated is high.23–25 Uncertain effects have been
demonstrated for chemotherapy alone.26–28
After vascular replacement, 3 of 11 grafts developed
thrombotic occlusion and required reoperation. The pa-
tency of the prosthetic replacement was evaluated by
imaging in five patients. We interpret the lack of clinical
symptoms of graft occlusion in the others as evidence of
a patent replacement because occlusion of a major ret-
roperitoneal vascular replacement usually becomes
symptomatic.
Our general approach includes intravenous adminis-
tration of heparin sodium immediately after aortic and
vena cava graft replacement. This is followed by post-
operative lifelong chronic antiplatelet therapy in patients
with an aortic graft. Oral anticoagulation of undetermined
duration is given after vena cava replacement. However,
in the present series with concomitant resection of tu-
mors, individual tailoring of treatment according to an
interdisciplinary discussion resulted in postoperative
administration of low-molecular-weight heparin alone in
three patients. In this series there were no other graft-
related complications, nor were there any later deaths or
complications as a result of vascular patency failure.
CONCLUSIONS
We believe that these results justify an extended sur-
gical approach to retroperitoneal neoplasms, including
prosthetic vascular replacement, because early morbidity
and mortality were low and graft patency did not limit the
late course of the disease. We also believe that prosthetic
replacement of the infrarenal aorta or inferior vena cava
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(or both) is a safe option with few graft-related compli-
cations. Because it provides the only chance of control-
ling advanced retroperitoneal tumors, we favor this
aggressive surgical management.
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